User profiles for L. W. Ellisen
Leif W. EllisenProfessor of Medicine, Harvard Medical School Verified email at mgh.harvard.edu Cited by 27854 |
[HTML][HTML] The molecular pathogenesis of head and neck squamous cell carcinoma
SM Rothenberg, LW Ellisen - The Journal of clinical …, 2012 - Am Soc Clin Investig
… Lori Wirth and members of the Ellisen laboratory for helpful discussions and review of the
manuscript. This work was supported by NIH R01 DE-015945 (to LW Ellisen) and by NIH K08 …
manuscript. This work was supported by NIH R01 DE-015945 (to LW Ellisen) and by NIH K08 …
p63 and p73 in human cancer: defining the network
MP Deyoung, LW Ellisen - Oncogene, 2007 - nature.com
The p53-related genes p63 and p73 exhibit significant structural homology to p53; however,
they do not function as classical tumor suppressors and are rarely mutated in human …
they do not function as classical tumor suppressors and are rarely mutated in human …
Neoadjuvant endocrine therapy for estrogen receptor–positive breast cancer: a systematic review and meta-analysis
…, A Gupta, KL Reynolds, MA Gadd, LW Ellisen… - JAMA …, 2016 - jamanetwork.com
Importance Estrogen receptor–positive (ER+) tumors of the breast are generally highly
responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant …
responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant …
[HTML][HTML] hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
Telomerase, the ribonucleoprotein enzyme that elongates telomeres, is repressed in normal
human somatic cells but is reactivated during tumor progression. We report the cloning of a …
human somatic cells but is reactivated during tumor progression. We report the cloning of a …
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms
LW Ellisen, J Bird, DC West, AL Soreng, TC Reynolds… - Cell, 1991 - cell.com
Previously we described joining of DNA in the 9 T cell receptor gene to DNA of an
uncharacterized locus in at (7; 9)(q34; q34. 3) chromosomal translocation from a case of human T …
uncharacterized locus in at (7; 9)(q34; q34. 3) chromosomal translocation from a case of human T …
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
…, E Hafen, LA Witters, LW Ellisen… - Genes & …, 2004 - genesdev.cshlp.org
… Lei and LW Ellisen, in prep.). In contrast to Redd1 +/+ MEFs, Redd1 -/- MEFs failed to down-…
Both Redd1 and Redd2 are expressed during development (Ellisen et al. 2002). However, …
Both Redd1 and Redd2 are expressed during development (Ellisen et al. 2002). However, …
[HTML][HTML] Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment.
As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-…
As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-…
[HTML][HTML] The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α
SIRT6 is a member of a highly conserved family of NAD + -dependent deacetylases with
various roles in metabolism, stress resistance, and life span. SIRT6-deficient mice develop …
various roles in metabolism, stress resistance, and life span. SIRT6-deficient mice develop …
Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling
…, P Horak, A Sofer, D Sgroi, LW Ellisen - Genes & …, 2008 - genesdev.cshlp.org
Hypoxia induces rapid and dramatic changes in cellular metabolism, in part through inhibition
of target of rapamycin (TOR) kinase complex 1 (TORC1) activity. Genetic studies have …
of target of rapamycin (TOR) kinase complex 1 (TORC1) activity. Genetic studies have …
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Cancers of origin in the gallbladder and bile ducts are rarely curable with current modalities
of cancer treatment. Our clinical application of broad-based mutational profiling for patients …
of cancer treatment. Our clinical application of broad-based mutational profiling for patients …